NASDAQ:AXLA

Axcella Health (AXLA) Stock Forecast, Price & News

$0.37

0.00 (0.00%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.35
▼
$0.37
50-Day Range: $0.35
▼
$0.50
52-Week Range: $0.16
▼
$2.79

Volume: 68,006 shs
Average Volume: 38,280 shs
Market Capitalization: $26.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.25

Axcella Health MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,337.6% Upside
$5.25 Price Target
Short Interest: Bearish
5.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.49) to ($1.35) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars

Medical Sector

916th out of 983 stocks

Biological Products, Except Diagnostic Industry

155th out of 164 stocks

3.3

Analyst's Opinion

Consensus Rating
Axcella Health has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.25, Axcella Health has a forecasted upside of 1,337.6% from its current price of $0.37.
Amount of Analyst Coverage
Axcella Health has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
5.75% of the float of Axcella Health has been sold short.
Short Interest Ratio / Days to Cover
Axcella Health has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Axcella Health has recently increased by 1.32%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Axcella Health does not currently pay a dividend.
Dividend Growth
Axcella Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AXLA.

N/A

News and Social Media Coverage

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axcella Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.50% of the stock of Axcella Health is held by insiders.
Percentage Held by Institutions
71.05% of the stock of Axcella Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Axcella Health are expected to decrease in the coming year, from ($0.49) to ($1.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axcella Health is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axcella Health is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axcella Health has a P/B Ratio of 36.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Axcella Health (NASDAQ:AXLA) Stock

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

AXLA Stock News Headlines

May 12, 2023 | americanbankingnews.com

HC Wainwright Brokers Lift Earnings Estimates for Axcella Health Inc. (NASDAQ:AXLA)

May 8, 2023 | markets.businessinsider.com

Axcella Health (AXLA) Gets a Hold from H.C. Wainwright

June 3, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

April 17, 2023 | finance.yahoo.com

Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023

April 14, 2023 | finance.yahoo.com

Big Bank's Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today's Top Stories

April 14, 2023 | msn.com

Long COVID-Fatigue Impacts 50M People - Axcella Health Seeks Funding To Support Drug Development

April 5, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for Axcella Health Inc. (NASDAQ:AXLA) Issued By HC Wainwright

April 4, 2023 | americanbankingnews.com

Axcella Health Inc. Forecasted to Earn FY2027 Earnings of ($1.38) Per Share (NASDAQ:AXLA)

June 3, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

April 3, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Hold Rating on Axcella Health (AXLA)

April 1, 2023 | benzinga.com

Axcella Health Q4 EPS $(0.33) Misses $(0.30) Estimate; Cash & Cash Equivalents Of Sufficient To Operate Into Q2 Of 2023

April 1, 2023 | americanbankingnews.com

Axcella Health Inc. (NASDAQ:AXLA) Short Interest Update

March 30, 2023 | benzinga.com

Axcella Health shares are trading higher after the company reported Q4 financial results.

March 30, 2023 | finance.yahoo.com

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 16, 2023 | markets.businessinsider.com

Noble Financial Keeps Their Buy Rating on Axcella Health (AXLA)

February 16, 2023 | msn.com

Why Is Axcella Health (AXLA) Stock Up 35% Today?

February 15, 2023 | finance.yahoo.com

Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

February 9, 2023 | finance.yahoo.com

Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference

January 25, 2023 | finance.yahoo.com

With lean staff, low cash, Axcella races ahead with Long Covid drug

January 24, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Axcella Health (AXLA)

January 24, 2023 | investorplace.com

Why Is Axcella Health (AXLA) Stock Up 66% Today?

January 23, 2023 | marketwatch.com

Axcella Health Shares Surge 53% on U.K. Regulator Guidance on AXA1125 for Long Covid Fatigue

January 23, 2023 | finance.yahoo.com

Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

December 23, 2022 | finance.yahoo.com

Axcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85%

December 15, 2022 | finance.yahoo.com

Axcella Announces Program Reprioritization and Corporate Restructuring

November 11, 2022 | finance.yahoo.com

Axcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

November 4, 2022 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Axcella Health (AXLA)

See More Headlines

AXLA Price History

30 days | 90 days | 365 days | Advanced Chart

AXLA Company Calendar

Last Earnings: 3/30/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AXLA
CUSIP: N/A
CIK: 1633070
Web: www.axcellahealth.com
Phone: (857) 320-2200
Fax: 617-441-6243
Employees: 59
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.25
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +1,337.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-81,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -3,888.62%
Return on Assets: -229.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.07
Quick Ratio: 1.07

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.01 per share
Price / Book: 36.52

Miscellaneous

Outstanding Shares: 73,690,000
Free Float: 68,897,000
Market Cap: $26.91 million
Optionable: Not Optionable
Beta: 1.56

Key Executives

William R. Hinshaw
President, Chief Executive Officer & Director

Margaret Koziel
Chief Medical Officer & Senior Vice President

Paul Fehlner
Secretary, Chief Legal Officer & Senior VP

Dan Kirby
SVP-Strategic Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXLA Stock - Frequently Asked Questions

Should I buy or sell Axcella Health stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXLA shares.
View AXLA analyst ratings or view top-rated stocks.
What is Axcella Health's stock price forecast for 2023?: 4 brokers have issued 1 year target prices for Axcella Health's shares. Their AXLA share price forecasts range from $2.00 to $8.00. On average, they anticipate the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 1,337.6% from the stock's current price.
View analysts price targets for AXLA or view top-rated stocks among Wall Street analysts.
How have AXLA shares performed in 2023?: Axcella Health's stock was trading at $0.3275 on January 1st, 2023. Since then, AXLA shares have increased by 11.5% and is now trading at $0.3652.
View the best growth stocks for 2023 here.
When is Axcella Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our AXLA earnings forecast.
How were Axcella Health's earnings last quarter?: Axcella Health Inc. (NASDAQ:AXLA) posted its quarterly earnings results on Thursday, March, 30th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.06.
What is Bill Hinshaw's approval rating as Axcella Health's CEO?: 5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

What other stocks do shareholders of Axcella Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).
When did Axcella Health IPO?: (AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO.
What is Axcella Health's stock symbol?: Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."
Who are Axcella Health's major shareholders?: Axcella Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.46%), Virtu Financial LLC (0.11%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane and William Hinshaw.
View institutional ownership trends.
How do I buy shares of Axcella Health?: Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Axcella Health's stock price today?: One share of AXLA stock can currently be purchased for approximately $0.37.
How much money does Axcella Health make?: Axcella Health (NASDAQ:AXLA) has a market capitalization of $26.91 million. The company earns $-81,190,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.
How can I contact Axcella Health?: Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243.

This page (NASDAQ:AXLA) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial